APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-PD-1 MAb

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Anti-PD-1 MAb Market Analysis and Forecast 2026-2032

2 January 2026198 pages

Choose your research edition.

Industry ResearchAnti-PD-1 MAb Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-PD-1 MAb Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Anti-PD-1 MAb Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-PD-1 MAb Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-PD-1 MAb Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Anti-PD-1 MAb market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Anti-PD-1 MAb is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Anti-PD-1 MAb is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Anti-PD-1 MAb is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Anti-PD-1 MAb is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Anti-PD-1 MAb include Thermo Fisher Scientific, Merck KGaA, Ximbio, Sino Biological, OriGene Technologies, Leinco Technologies, Elabscience and BioVision, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Anti-PD-1 MAb, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti-PD-1 MAb, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti-PD-1 MAb, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-PD-1 MAb revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-PD-1 MAb market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Anti-PD-1 MAb revenue, projected growth trends, production technology, application and end-user industry.

Anti-PD-1 MAb Segment by Company

Thermo Fisher Scientific

Merck KGaA

Ximbio

Sino Biological

OriGene Technologies

Leinco Technologies

Elabscience

BioVision

Anti-PD-1 MAb Segment by Type

1mg

2.5mg

Others

Anti-PD-1 MAb Segment by Application

Pharmaceutical

Research

Other

Anti-PD-1 MAb Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-PD-1 MAb market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-PD-1 MAb and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-PD-1 MAb.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Anti-PD-1 MAb in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Anti-PD-1 MAb company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-PD-1 MAb revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti-PD-1 MAb Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 1mg Major Player Table 3. 2.5mg Major Player Table 4. Others Major Player Table 5. Global Anti-PD-1 MAb Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Pharmaceutical Major Player Table 7. Research Major Player Table 8. Other Major Player Table 9. Anti-PD-1 MAb Industry Trends Table 10. Anti-PD-1 MAb Industry Drivers Table 11. Anti-PD-1 MAb Industry Opportunities and Challenges Table 12. Anti-PD-1 MAb Industry Restraints Table 13. Global Anti-PD-1 MAb Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Anti-PD-1 MAb Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Anti-PD-1 MAb Market Share by Region (2021-2026) Table 16. Global Anti-PD-1 MAb Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Anti-PD-1 MAb Market Share by Region (2027-2032) Table 18. Global Anti-PD-1 MAb Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Anti-PD-1 MAb Revenue Market Share by Players (2021-2026) Table 20. Global Anti-PD-1 MAb Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Anti-PD-1 MAb Key Players Headquarters & Area Served Table 22. Global Anti-PD-1 MAb Players, Product Type & Application Table 23. Global Anti-PD-1 MAb Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Anti-PD-1 MAb by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Anti-PD-1 MAb Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Anti-PD-1 MAb Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Anti-PD-1 MAb Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Anti-PD-1 MAb Revenue Market Share by Type (2021-2026) Table 30. Global Anti-PD-1 MAb Revenue Market Share by Type (2027-2032) Table 31. Global Anti-PD-1 MAb Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Anti-PD-1 MAb Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Anti-PD-1 MAb Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Anti-PD-1 MAb Revenue Market Share by Application (2021-2026) Table 35. Global Anti-PD-1 MAb Revenue Market Share by Application (2027-2032) Table 36. Thermo Fisher Scientific Company Information Table 37. Thermo Fisher Scientific Business Overview Table 38. Thermo Fisher Scientific Anti-PD-1 MAb Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Thermo Fisher Scientific Anti-PD-1 MAb Product Portfolio Table 40. Thermo Fisher Scientific Recent Development Table 41. Merck KGaA Company Information Table 42. Merck KGaA Business Overview Table 43. Merck KGaA Anti-PD-1 MAb Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Merck KGaA Anti-PD-1 MAb Product Portfolio Table 45. Merck KGaA Recent Development Table 46. Ximbio Company Information Table 47. Ximbio Business Overview Table 48. Ximbio Anti-PD-1 MAb Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Ximbio Anti-PD-1 MAb Product Portfolio Table 50. Ximbio Recent Development Table 51. Sino Biological Company Information Table 52. Sino Biological Business Overview Table 53. Sino Biological Anti-PD-1 MAb Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Sino Biological Anti-PD-1 MAb Product Portfolio Table 55. Sino Biological Recent Development Table 56. OriGene Technologies Company Information Table 57. OriGene Technologies Business Overview Table 58. OriGene Technologies Anti-PD-1 MAb Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. OriGene Technologies Anti-PD-1 MAb Product Portfolio Table 60. OriGene Technologies Recent Development Table 61. Leinco Technologies Company Information Table 62. Leinco Technologies Business Overview Table 63. Leinco Technologies Anti-PD-1 MAb Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Leinco Technologies Anti-PD-1 MAb Product Portfolio Table 65. Leinco Technologies Recent Development Table 66. Elabscience Company Information Table 67. Elabscience Business Overview Table 68. Elabscience Anti-PD-1 MAb Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Elabscience Anti-PD-1 MAb Product Portfolio Table 70. Elabscience Recent Development Table 71. BioVision Company Information Table 72. BioVision Business Overview Table 73. BioVision Anti-PD-1 MAb Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. BioVision Anti-PD-1 MAb Product Portfolio Table 75. BioVision Recent Development Table 76. North America Anti-PD-1 MAb Revenue by Type (2021-2026) & (US$ Million) Table 77. North America Anti-PD-1 MAb Revenue by Type (2027-2032) & (US$ Million) Table 78. North America Anti-PD-1 MAb Revenue by Application (2021-2026) & (US$ Million) Table 79. North America Anti-PD-1 MAb Revenue by Application (2027-2032) & (US$ Million) Table 80. North America Anti-PD-1 MAb Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 81. North America Anti-PD-1 MAb Revenue by Country (2021-2026) & (US$ Million) Table 82. North America Anti-PD-1 MAb Revenue by Country (US$ Million) & (2027-2032) Table 83. Europe Anti-PD-1 MAb Revenue by Type (2021-2026) & (US$ Million) Table 84. Europe Anti-PD-1 MAb Revenue by Type (2027-2032) & (US$ Million) Table 85. Europe Anti-PD-1 MAb Revenue by Application (2021-2026) & (US$ Million) Table 86. Europe Anti-PD-1 MAb Revenue by Application (2027-2032) & (US$ Million) Table 87. Europe Anti-PD-1 MAb Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Europe Anti-PD-1 MAb Revenue by Country (2021-2026) & (US$ Million) Table 89. Europe Anti-PD-1 MAb Revenue by Country (US$ Million) & (2027-2032) Table 90. China Anti-PD-1 MAb Revenue by Type (2021-2026) & (US$ Million) Table 91. China Anti-PD-1 MAb Revenue by Type (2027-2032) & (US$ Million) Table 92. China Anti-PD-1 MAb Revenue by Application (2021-2026) & (US$ Million) Table 93. China Anti-PD-1 MAb Revenue by Application (2027-2032) & (US$ Million) Table 94. Asia Anti-PD-1 MAb Revenue by Type (2021-2026) & (US$ Million) Table 95. Asia Anti-PD-1 MAb Revenue by Type (2027-2032) & (US$ Million) Table 96. Asia Anti-PD-1 MAb Revenue by Application (2021-2026) & (US$ Million) Table 97. Asia Anti-PD-1 MAb Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia Anti-PD-1 MAb Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Asia Anti-PD-1 MAb Revenue by Region (US$ Million) & (2021-2026) Table 100. Asia Anti-PD-1 MAb Revenue by Region (US$ Million) & (2027-2032) Table 101. SAMEA Anti-PD-1 MAb Revenue by Type (2021-2026) & (US$ Million) Table 102. SAMEA Anti-PD-1 MAb Revenue by Type (2027-2032) & (US$ Million) Table 103. SAMEA Anti-PD-1 MAb Revenue by Application (2021-2026) & (US$ Million) Table 104. SAMEA Anti-PD-1 MAb Revenue by Application (2027-2032) & (US$ Million) Table 105. SAMEA Anti-PD-1 MAb Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. SAMEA Anti-PD-1 MAb Revenue by Country (2021-2026) & (US$ Million) Table 107. SAMEA Anti-PD-1 MAb Revenue by Country (US$ Million) & (2027-2032) Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Anti-PD-1 MAb Image Figure 2. Global Anti-PD-1 MAb Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-PD-1 MAb Market Size Share 2021 VS 2025 VS 2032 Figure 4. 1mg Image Figure 5. 2.5mg Image Figure 6. Others Image Figure 7. Global Anti-PD-1 MAb Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Anti-PD-1 MAb Market Size Share 2021 VS 2025 VS 2032 Figure 9. Pharmaceutical Image Figure 10. Research Image Figure 11. Other Image Figure 12. Global Anti-PD-1 MAb Market Size (US$ Million) & (2021-2032) Figure 13. Global Anti-PD-1 MAb Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Anti-PD-1 MAb Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Anti-PD-1 MAb Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Anti-PD-1 MAb Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Anti-PD-1 MAb Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Anti-PD-1 MAb Revenue Market Share by Type (2021-2032) Figure 20. Global Anti-PD-1 MAb Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Anti-PD-1 MAb Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Anti-PD-1 MAb Revenue Market Share by Application (2021-2032) Figure 23. North America Anti-PD-1 MAb Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Anti-PD-1 MAb Revenue Share by Type (2021-2032) Figure 25. North America Anti-PD-1 MAb Revenue Share by Application (2021-2032) Figure 26. North America Anti-PD-1 MAb Revenue Share by Country (2021-2032) Figure 27. United States Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Anti-PD-1 MAb Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Anti-PD-1 MAb Revenue Share by Type (2021-2032) Figure 32. Europe Anti-PD-1 MAb Revenue Share by Application (2021-2032) Figure 33. Europe Anti-PD-1 MAb Revenue Share by Country (2021-2032) Figure 34. Germany Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Anti-PD-1 MAb Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Anti-PD-1 MAb Revenue Share by Type (2021-2032) Figure 44. China Anti-PD-1 MAb Revenue Share by Application (2021-2032) Figure 45. Asia Anti-PD-1 MAb Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Anti-PD-1 MAb Revenue Share by Type (2021-2032) Figure 47. Asia Anti-PD-1 MAb Revenue Share by Application (2021-2032) Figure 48. Asia Anti-PD-1 MAb Revenue Share by Region (2021-2032) Figure 49. Japan Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Anti-PD-1 MAb Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Anti-PD-1 MAb Revenue Share by Type (2021-2032) Figure 57. SAMEA Anti-PD-1 MAb Revenue Share by Application (2021-2032) Figure 58. SAMEA Anti-PD-1 MAb Revenue Share by Country (2021-2032) Figure 59. Brazil Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Anti-PD-1 MAb Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 1mg
  • 2.5mg
  • Others
Applications
  • Pharmaceutical
  • Research
  • Other
Companies covered
  • Thermo Fisher Scientific
  • Merck KGaA
  • Ximbio
  • Sino Biological
  • OriGene Technologies
  • Leinco Technologies
  • Elabscience
  • BioVision

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti-PD-1 MAb Market by Type
  3. 1.2.1 Global Anti-PD-1 MAb Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 1mg
  5. 1.2.3 2.5mg
  6. 1.2.4 Others
  7. 1.3 Anti-PD-1 MAb Market by Application
  8. 1.3.1 Global Anti-PD-1 MAb Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Pharmaceutical
  10. 1.3.3 Research
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Anti-PD-1 MAb Market Dynamics
  1. 2.1 Anti-PD-1 MAb Industry Trends
  2. 2.2 Anti-PD-1 MAb Industry Drivers
  3. 2.3 Anti-PD-1 MAb Industry Opportunities and Challenges
  4. 2.4 Anti-PD-1 MAb Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Anti-PD-1 MAb Market Perspective (2021-2032)
  2. 3.2 Global Anti-PD-1 MAb Growth Trends by Region
  3. 3.2.1 Global Anti-PD-1 MAb Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti-PD-1 MAb Market Size by Region (2021-2026)
  5. 3.2.3 Global Anti-PD-1 MAb Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Anti-PD-1 MAb Revenue by Players
  2. 4.1.1 Global Anti-PD-1 MAb Revenue by Players (2021-2026)
  3. 4.1.2 Global Anti-PD-1 MAb Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Anti-PD-1 MAb Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti-PD-1 MAb Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Anti-PD-1 MAb Key Players Headquarters & Area Served
  7. 4.4 Global Anti-PD-1 MAb Players, Product Type & Application
  8. 4.5 Global Anti-PD-1 MAb Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Anti-PD-1 MAb Market CR5 and HHI
  11. 4.6.3 2025 Anti-PD-1 MAb Tier 1, Tier 2, and Tier 3
5 Anti-PD-1 MAb Market Size by Type
  1. 5.1 Global Anti-PD-1 MAb Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Anti-PD-1 MAb Revenue by Type (2021-2032)
  3. 5.3 Global Anti-PD-1 MAb Revenue Market Share by Type (2021-2032)
6 Anti-PD-1 MAb Market Size by Application
  1. 6.1 Global Anti-PD-1 MAb Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Anti-PD-1 MAb Revenue by Application (2021-2032)
  3. 6.3 Global Anti-PD-1 MAb Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Thermo Fisher Scientific
  2. 7.1.1 Thermo Fisher Scientific Company Information
  3. 7.1.2 Thermo Fisher Scientific Business Overview
  4. 7.1.3 Thermo Fisher Scientific Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Thermo Fisher Scientific Anti-PD-1 MAb Product Portfolio
  6. 7.1.5 Thermo Fisher Scientific Recent Developments
  7. 7.2 Merck KGaA
  8. 7.2.1 Merck KGaA Company Information
  9. 7.2.2 Merck KGaA Business Overview
  10. 7.2.3 Merck KGaA Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck KGaA Anti-PD-1 MAb Product Portfolio
  12. 7.2.5 Merck KGaA Recent Developments
  13. 7.3 Ximbio
  14. 7.3.1 Ximbio Company Information
  15. 7.3.2 Ximbio Business Overview
  16. 7.3.3 Ximbio Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Ximbio Anti-PD-1 MAb Product Portfolio
  18. 7.3.5 Ximbio Recent Developments
  19. 7.4 Sino Biological
  20. 7.4.1 Sino Biological Company Information
  21. 7.4.2 Sino Biological Business Overview
  22. 7.4.3 Sino Biological Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sino Biological Anti-PD-1 MAb Product Portfolio
  24. 7.4.5 Sino Biological Recent Developments
  25. 7.5 OriGene Technologies
  26. 7.5.1 OriGene Technologies Company Information
  27. 7.5.2 OriGene Technologies Business Overview
  28. 7.5.3 OriGene Technologies Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  29. 7.5.4 OriGene Technologies Anti-PD-1 MAb Product Portfolio
  30. 7.5.5 OriGene Technologies Recent Developments
  31. 7.6 Leinco Technologies
  32. 7.6.1 Leinco Technologies Company Information
  33. 7.6.2 Leinco Technologies Business Overview
  34. 7.6.3 Leinco Technologies Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Leinco Technologies Anti-PD-1 MAb Product Portfolio
  36. 7.6.5 Leinco Technologies Recent Developments
  37. 7.7 Elabscience
  38. 7.7.1 Elabscience Company Information
  39. 7.7.2 Elabscience Business Overview
  40. 7.7.3 Elabscience Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Elabscience Anti-PD-1 MAb Product Portfolio
  42. 7.7.5 Elabscience Recent Developments
  43. 7.8 BioVision
  44. 7.8.1 BioVision Company Information
  45. 7.8.2 BioVision Business Overview
  46. 7.8.3 BioVision Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  47. 7.8.4 BioVision Anti-PD-1 MAb Product Portfolio
  48. 7.8.5 BioVision Recent Developments
8 North America
  1. 8.1 North America Anti-PD-1 MAb Revenue (2021-2032)
  2. 8.2 North America Anti-PD-1 MAb Revenue by Type (2021-2032)
  3. 8.2.1 North America Anti-PD-1 MAb Revenue by Type (2021-2026)
  4. 8.2.2 North America Anti-PD-1 MAb Revenue by Type (2027-2032)
  5. 8.3 North America Anti-PD-1 MAb Revenue Share by Type (2021-2032)
  6. 8.4 North America Anti-PD-1 MAb Revenue by Application (2021-2032)
  7. 8.4.1 North America Anti-PD-1 MAb Revenue by Application (2021-2026)
  8. 8.4.2 North America Anti-PD-1 MAb Revenue by Application (2027-2032)
  9. 8.5 North America Anti-PD-1 MAb Revenue Share by Application (2021-2032)
  10. 8.6 North America Anti-PD-1 MAb Revenue by Country
  11. 8.6.1 North America Anti-PD-1 MAb Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Anti-PD-1 MAb Revenue by Country (2021-2026)
  13. 8.6.3 North America Anti-PD-1 MAb Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Anti-PD-1 MAb Revenue (2021-2032)
  2. 9.2 Europe Anti-PD-1 MAb Revenue by Type (2021-2032)
  3. 9.2.1 Europe Anti-PD-1 MAb Revenue by Type (2021-2026)
  4. 9.2.2 Europe Anti-PD-1 MAb Revenue by Type (2027-2032)
  5. 9.3 Europe Anti-PD-1 MAb Revenue Share by Type (2021-2032)
  6. 9.4 Europe Anti-PD-1 MAb Revenue by Application (2021-2032)
  7. 9.4.1 Europe Anti-PD-1 MAb Revenue by Application (2021-2026)
  8. 9.4.2 Europe Anti-PD-1 MAb Revenue by Application (2027-2032)
  9. 9.5 Europe Anti-PD-1 MAb Revenue Share by Application (2021-2032)
  10. 9.6 Europe Anti-PD-1 MAb Revenue by Country
  11. 9.6.1 Europe Anti-PD-1 MAb Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Anti-PD-1 MAb Revenue by Country (2021-2026)
  13. 9.6.3 Europe Anti-PD-1 MAb Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Anti-PD-1 MAb Revenue (2021-2032)
  2. 10.2 China Anti-PD-1 MAb Revenue by Type (2021-2032)
  3. 10.2.1 China Anti-PD-1 MAb Revenue by Type (2021-2026)
  4. 10.2.2 China Anti-PD-1 MAb Revenue by Type (2027-2032)
  5. 10.3 China Anti-PD-1 MAb Revenue Share by Type (2021-2032)
  6. 10.4 China Anti-PD-1 MAb Revenue by Application (2021-2032)
  7. 10.4.1 China Anti-PD-1 MAb Revenue by Application (2021-2026)
  8. 10.4.2 China Anti-PD-1 MAb Revenue by Application (2027-2032)
  9. 10.5 China Anti-PD-1 MAb Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti-PD-1 MAb Revenue (2021-2032)
  2. 11.2 Asia Anti-PD-1 MAb Revenue by Type (2021-2032)
  3. 11.2.1 Asia Anti-PD-1 MAb Revenue by Type (2021-2026)
  4. 11.2.2 Asia Anti-PD-1 MAb Revenue by Type (2027-2032)
  5. 11.3 Asia Anti-PD-1 MAb Revenue Share by Type (2021-2032)
  6. 11.4 Asia Anti-PD-1 MAb Revenue by Application (2021-2032)
  7. 11.4.1 Asia Anti-PD-1 MAb Revenue by Application (2021-2026)
  8. 11.4.2 Asia Anti-PD-1 MAb Revenue by Application (2027-2032)
  9. 11.5 Asia Anti-PD-1 MAb Revenue Share by Application (2021-2032)
  10. 11.6 Asia Anti-PD-1 MAb Revenue by Country
  11. 11.6.1 Asia Anti-PD-1 MAb Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Anti-PD-1 MAb Revenue by Country (2021-2026)
  13. 11.6.3 Asia Anti-PD-1 MAb Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti-PD-1 MAb Revenue (2021-2032)
  2. 12.2 SAMEA Anti-PD-1 MAb Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Anti-PD-1 MAb Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Anti-PD-1 MAb Revenue by Type (2027-2032)
  5. 12.3 SAMEA Anti-PD-1 MAb Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Anti-PD-1 MAb Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Anti-PD-1 MAb Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Anti-PD-1 MAb Revenue by Application (2027-2032)
  9. 12.5 SAMEA Anti-PD-1 MAb Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Anti-PD-1 MAb Revenue by Country
  11. 12.6.1 SAMEA Anti-PD-1 MAb Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Anti-PD-1 MAb Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Anti-PD-1 MAb Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst